Alphabet's valuation looks high, but the catalysts suggest shares remain undervalued. Google Cloud's AI-driven backlog signals accelerating multi-year revenue growth for GOOGL. TPUs could evolve into ...

With the holiday season fully swinging, we are officially in the most sentimental time of year, and Zeds Dead knows it. The pair spent more than a year making the six-and-a-half-minute clip. Watch it ...

Strictly Come Dancing fans are unhappy with the outcome of this week's Dance Off, which has yet to air on TV but has been leaked online. Confused? Well, although the Dance Off is presented as live on ...

We may earn commission from links on this page, but we only recommend products we love. Promise. Whether it was the joy of seeing the pen swirl round and round to create a spiral or all the wild ...

The comedy troupe 30 Minute Musicals (30MM) will present, with tongue-in-cheek charm, a hilarious musical mash-up of Home Alone, condensed into a rapid-fire, music-packed distillation of the ...

“Monster Mash” was originally written as a parody of several pop fads that have faded away, but the song is an American novelty song that lives on like a vampire. In the early 1960s two cultural ...

If developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) were a poker game, you could say Novo Nordisk (NASDAQ Copenhagen: NOVO-B) saw a competitor’s bet and raised the stakes ...

“First of all, it was October” is how Something Wicked This Way Comes begins, and while Halloween is barely mentioned by name, the movie is drenched in the spirit of spooky season. It’s framed as a ...

Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook When beloved television series end, the story may be over but for fans things are never really ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Roche has scooped up 89bio and its phase III FGF21 analogue pegozafermin, as drug developers continue to race to advance new drugs for the liver disease metabolic dysfunction-associated ...